文章摘要

依达拉奉治疗不影响不同尿酸水平急性缺血性卒中患者的预后

作者: 1周 华祥, 1吴 悦欣, 1樊 福强
1 滨州市第二人民医院(沾化区人民医院)神经内科,山东 滨州 256800
通讯: 吴 悦欣 Email: wuyuexin2541@aliyun.com
DOI: 10.3978/j.issn.2095-6959.2020.02.013

摘要

目的:探讨依达拉奉治疗急性缺血性卒中患者尿酸水平与90 d时临床结局的关系。方法:回顾性研究发病24 h内入院的且改良Rankin量表(Modified Rankin Scale,MRS)评分<2的缺血性卒中患者。以尿酸水平中位数值(333 μmol/L)作为临界值将患者分为低尿酸(≤333 μmol/L)组和高尿酸(>333 μmol/L)组,并比较了90 d时两组患者的临床资料及良好预后(MRS<2)的关系。进一步研究使用及未使用依达拉奉的尿酸水平与90 d时结局指标之间的关系。结果:高尿酸组男性、高血压、心房颤动和心源性卒中的比例高于低尿酸组。高尿酸组90 d时MRS<2的患者比例也较高(P=0.013);但在多因素分析中,尿酸与良好结局指标之间无独立相关性(OR 1.30,95%CI:0.94~1.71)。在亚组分析中,高尿酸组中未使用依达拉奉治疗的患者90 d时MRS<2的人数多于低尿酸组(OR 2.87,95%CI:1.20~7.16),但使用依达拉奉的高尿酸组与低尿酸组患者之间则无相关性。结论:在急性缺血性卒中患者中,依达拉奉治疗后90 d时高尿酸水平与良好预后之间的关系不明显。
关键词: 尿酸;依达拉奉;急性缺血性脑卒中

Edaravone treatment does not impact outcome of acute ischemic stroke patients with different uric acid levels

Authors: 1ZHOU Huaxiang, 1WU Yuexin, 1FAN Fuqiang
1 Department of Neurology, Binzhou Second People’s Hospital (Zhanhua District People’s Hospital), Binzhou Shandong 256800, China

CorrespondingAuthor:WU Yuexin Email: wuyuexin2541@aliyun.com

Abstract

Objective: To investigated whether the use of edaravone affected the relationship between uric acid levels and outcome at 90 days in patients with acute ischemic stroke. Methods: Consecutive ischemic stroke patients with modified Rankin Scale (MRS) scores <2 admitted within 24 h were evaluated by retrospective analysis. The patients were divided into low uric acid (≤333 μmol/L) group and high uric acid (>333 μmol/L) group according to the median uric acid level (333 μmol/L) as a cutoff. And, compared the clinical characteristics and favorable outcomes (MRS <2) in the 2 groups at 90 days. The relationship between uric acid levels and 90-day stroke outcome in patients with or without edaravone treatment was further investigated. Results: The high uric acid group had a higher proportion of men, hypertension, atrial fibrillation, and cardioembolic stroke than the low uric acid group. The high uric acid group also had a higher proportion of patients with MRS <2 at 90 days (P=0.013), however, However, there was no independent correlation between uric acid and good outcome indicators in multivariate analysis (OR 1.30, 95% CI: 0.94–1.71). In subgroup analysis, the high uric acid group without edaravone exhibited a higher proportion of patients with MRS <2 at 90 days than the low uric acid group (OR 2.87, 95% CI: 1.20–7.16), however, the high uric acid group with edaravone did not exhibit this difference. Conclusion: In acute ischemic stroke, the favorable association between high uric acid levels and outcome at 90 days was not evident in patients treated with edaravone.
Keywords: uric acid; edaravone; acute ischemic stroke